Upadacitinib Optimization in a Patient With Protein-Losing Enteropathy Secondary to (Transient) Nonocclusive Mesenteric Ischemia, Idiopathic Myointimal Hyperplasia, and Hemodialysis
Although TDM for Janus-kinase inhibitors is not yet a part of current clinical practice, in this case, the measurement of upadacitinib serum concentrations aided individualized dosing based on TDM.
Authors
- Michiel Voskuil (ORCID: https://orcid.org/0000-0001-9285-9573)
- Daan J. Touw (ORCID: https://orcid.org/0000-0002-1429-4789)
- Johannes A. Kroes (ORCID: https://orcid.org/0000-0002-9418-4861)
- Christina Krikke
- Gerard Dijkstra
- Marijn C. Visschedijk (ORCID: https://orcid.org/0000-0001-7277-7677)
- Erin H. Smeijsters (ORCID: https://orcid.org/0000-0002-5264-5228)
- Paola Mian (ORCID: https://orcid.org/0000-0002-3551-1201)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Utrecht University (NL)
- Medisch Centrum Leeuwarden (NL)
- University Medical Center Utrecht (NL)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1097/ftd.0000000000001326
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00